{"id": "179618", "url": "https://fevir.net/resources/Library/179618", "date": "2023-11-26T18:15:27.442Z", "meta": {"profile": ["http://hl7.org/fhir/uv/ebm/StructureDefinition/systematic-review-included-studies"], "versionId": "3", "lastUpdated": "2023-11-26T21:01:14.757Z"}, "type": {"coding": [{"code": "asset-collection", "system": "http://terminology.hl7.org/CodeSystem/library-type", "display": "Asset Collection"}]}, "title": "SystematicReviewIncludedStudies: ADT and Docetaxel vs. ADT alone for metastatic hormone-naive prostate cancer", "author": [{"name": "Brian S. Alper"}], "status": "active", "contact": [{"telecom": [{"value": "support@computablepublishing.com", "system": "email"}]}], "copyright": "https://creativecommons.org/licenses/by-nc-sa/4.0/", "extension": [{"url": "http://hl7.org/fhir/uv/ebm/StructureDefinition/artifact-publication-status", "valueCodeableConcept": {"coding": [{"code": "active", "system": "http://terminology.hl7.org/CodeSystem/cited-artifact-status-type", "display": "Active"}]}}], "publisher": "Computable Publishing LLC", "identifier": [{"type": {"text": "FEvIR Object Identifier", "coding": [{"system": "http://terminology.hl7.org/CodeSystem/v2-0203", "code": "ACSN", "display": "Accession ID"}]}, "value": "179618", "system": "https://fevir.net/FOI", "assigner": {"display": "Computable Publishing LLC"}}], "useContext": [{"code": {"code": "evidence-communication", "system": "https://fevir.net/resources/CodeSystem/179423", "display": "Evidence Communication"}, "valueCodeableConcept": {"coding": [{"code": "SystematicReviewIncludedStudies", "system": "https://fevir.net/resources/CodeSystem/179423", "display": "SystematicReviewIncludedStudies"}]}}], "description": "3 included studies", "resourceType": "Library", "relatedArtifact": [{"type": "derived-from", "resourceReference": {"type": "Citation", "display": "27308831 Efficacy and Safety of Combined Androgen Deprivation Therapy (ADT) and Docetaxel Compared with ADT Alone for Metastatic Hormone-Naive Prostate Cancer: A Systematic Review and Meta-Analysis.", "reference": "Citation/179613"}}, {"type": "contains", "resourceReference": {"type": "Citation", "display": "23306100 Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial.", "reference": "Citation/179615"}}, {"type": "contains", "resourceReference": {"type": "Citation", "display": "25301760 Survival with Newly Diagnosed Metastatic Prostate Cancer in the 'Docetaxel Era': Data from 917 Patients in the Control Arm of the STAMPEDE Trial (MRC PR08, CRUK/06/019).", "reference": "Citation/179617"}}, {"type": "contains", "resourceReference": {"type": "Citation", "display": "26244877 Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer.", "reference": "Citation/179616"}}], "subjectReference": {"type": "Group", "display": "SystematicReviewEligibilityCriteria: ADT and Docetaxel vs. ADT alone for metastatic hormone-naive prostate cancer", "reference": "Group/179619"}}